2-Aryl hydrazonopropanal pharmacophores as potent cytotoxic agents against human hepatocellular carcinoma cell line
- 26 Downloads
The versatile synthon E-methyl 2-(2-(1,3-dioxo-1-arylpropan-2-ylidene) hydrazinyl) benzoate has a potent cytotoxic activity, which was screened in vitro for anticancer activity against human hepatocellular carcinoma cell (HCC) line. The results show a higher anticancer efficacy and higher selectivity index (SI) on HCC versus doxorubicin that warrants further studies in both animals and humans; this work has been patented.
KeywordsHepatocellular carcinoma 2-Aryl hydrazonopropanals Hydrazonopropanal derivative Doxorubicin Selectivity index (SI)
This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (P-0140-363-0436). The authors, therefore, acknowledged with thanks DSR technical and financial support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Al-Zaydi KM, Saleh TS, Bin Hadda T (2019) Potent cytotoxic agents against human hepatocellular carcinoma cell line based 2-aryl hydrazonopropanals pharmacophore. US Patent 10,280, 134B1Google Scholar
- Arnott JA, Kumar R, Planey SL (2013) Lipophilicity indices for drug Development. J Appl Biopharm Pharcokin 1:31–36Google Scholar
- Kaseb AO, Shindoh J, Patt YZ et al. (2013) Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil [PIAF] chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unrespectable hepatocellular carcinoma. Cancer 119:3334–3342CrossRefGoogle Scholar
- Kearns EH, Di L (2008) Drug-like properties: concepts, structure design and methods. Elsevier, USAGoogle Scholar
- Masriani M, Mustofa M, Jumina J, Sunarti S, Enawaty E (2014) Cytotoxic and pro-apoptotic activities of crude alkaloid from root of sengkubak (Pynarrhena cauliflora (Miers) Diels) in human breast cancer T47D cell line. Sch Acad J Biosci 2(5):336–340Google Scholar
- Yang TS, Lin YC, Chen JS et al. (2014) Phase II study of gemcitabine Oncol Rev 8:246, 31Google Scholar